

Thomas O Bergmeijer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6176541/publications.pdf>

Version: 2024-02-01

38
papers

1,427
citations

516215

16
h-index

329751

37
g-index

39
all docs

39
docs citations

39
times ranked

2208
citing authors

#	ARTICLE	IF	CITATIONS
1	A Genotype-Guided Strategy for Oral P2Y ₁₂ Inhibitors in Primary PCI. <i>New England Journal of Medicine</i> , 2019, 381, 1621-1631.	13.9	431
2	Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial. <i>Lancet</i> , The, 2020, 395, 1374-1381.	6.3	205
3	Derivation, Validation, and Prognostic Utility of a Prediction Rule for Nonresponse to Clopidogrel. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 606-617.	1.1	90
4	Reduction in Platelet Reactivity With Prasugrel 5 mg in Low-Body-Weight Patients Is Noninferior to Prasugrel 10 mg in Higher-Body-Weight Patients. <i>Journal of the American College of Cardiology</i> , 2012, 60, 2032-2040.	1.2	75
5	Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting. <i>Heart</i> , 2011, 97, 1239-1244.	1.2	72
6	CYP2C19 genotype-guided antiplatelet therapy in ST-segment elevation myocardial infarction patients Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study. <i>American Heart Journal</i> , 2014, 168, 16-22.e1.	1.2	71
7	Pharmacogenomic polygenic response score predicts ischaemic events and cardiovascular mortality in clopidogrel-treated patients. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 203-210.	1.4	69
8	Ticagrelor or prasugrel versus clopidogrel in elderly patients with an acute coronary syndrome: Optimization of antiplatelet treatment in patients 70 years and older Rationale and design of the POPular AGE study. <i>American Heart Journal</i> , 2015, 170, 981-985.e1.	1.2	43
9	Genomewide Association Study of Platelet Reactivity and Cardiovascular Response in Patients Treated With Clopidogrel: A Study by the International Clopidogrel Pharmacogenomics Consortium. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 1067-1077.	2.3	32
10	The impact of renal function on platelet reactivity and clinical outcome in patients undergoing percutaneous coronary intervention with stenting. <i>Thrombosis and Haemostasis</i> , 2014, 112, 1174-1181.	1.8	28
11	Impact of Selection Bias on Estimation of Subsequent Event Risk. <i>Circulation: Cardiovascular Genetics</i> , 2017, 10, .	5.1	28
12	The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease. <i>Thrombosis and Haemostasis</i> , 2014, 112, 589-597.	1.8	27
13	Incidence and Causes for Early Ticagrelor Discontinuation: A Real-World Dutch Registry Experience. <i>Cardiology</i> , 2017, 138, 164-168.	0.6	25
14	Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC). <i>American Heart Journal</i> , 2018, 198, 152-159.	1.2	24
15	Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events. <i>Circulation Genomic and Precision Medicine</i> , 2019, 12, e002471.	1.6	22
16	Feasibility and implementation of CYP2C19 genotyping in patients using antiplatelet therapy. <i>Pharmacogenomics</i> , 2018, 19, 621-628.	0.6	19
17	Subsequent Event Risk in Individuals With Established Coronary Heart Disease. <i>Circulation Genomic and Precision Medicine</i> , 2019, 12, e002470.	1.6	17
18	Higher body weight patients on clopidogrel maintenance therapy have lower active metabolite concentrations, lower levels of platelet inhibition, and higher rates of poor responders than low body weight patients. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 38, 127-36.	1.0	16

#	ARTICLE	IF	CITATIONS
19	Tailored P2Y12 inhibitor treatment in patients undergoing non-urgent PCI—the POPular Risk Score study. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 1201-1210.	0.8	16
20	The effect of correcting VerifyNow P2Y12 assay results for hematocrit in patients undergoing percutaneous coronary interventions. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 618-623.	1.9	15
21	Clopidogrel Versus Ticagrelor or Prasugrel After Primary Percutaneous Coronary Intervention According to CYP2C19 Genotype. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e009434.	1.4	14
22	Cost Effectiveness of a CYP2C19 Genotype-Guided Strategy in Patients with Acute Myocardial Infarction: Results from the POPular Genetics Trial. <i>American Journal of Cardiovascular Drugs</i> , 2022, 22, 195-206.	1.0	13
23	Association of Factor V Leiden With Subsequent Atherothrombotic Events. <i>Circulation</i> , 2020, 142, 546-555.	1.6	11
24	How Long Does It Take for Clopidogrel and Ticagrelor to Inhibit Platelets in Patients Undergoing Primary Percutaneous Coronary Intervention? A Detailed Pharmacodynamic Analysis: Time Course of Platelet Reactivity in STEMI (TOPS). <i>Seminars in Thrombosis and Hemostasis</i> , 2017, 43, 439-446.	1.5	9
25	Valor de la determinación del genotipo de CYP2C19 *2 y *17 en la práctica clínica. Prometedor, aunque todavía no está listo. <i>Revista Española De Cardiología</i> , 2012, 65, 205-207.	0.6	7
26	Perioperative management of antiplatelet treatment in patients undergoing isolated coronary artery bypass grafting in Dutch cardiothoracic centres. <i>Netherlands Heart Journal</i> , 2017, 25, 482-489.	0.3	7
27	A clinical risk score to identify patients at high risk of very late stent thrombosis. <i>Journal of Interventional Cardiology</i> , 2018, 31, 159-169.	0.5	6
28	Pre-hospital diagnosis, triage and treatment in patients with ST elevation myocardial infarction. <i>Heart</i> , 2012, 98, 1674-1678.	1.2	5
29	Prehospital treatment of ST-segment elevated myocardial infarction patients. <i>Future Cardiology</i> , 2013, 9, 229-241.	0.5	4
30	Clopidogrel in noncarriers of CYP2C19 loss-of-function alleles versus ticagrelor in elderly patients with acute coronary syndrome: A pre-specified sub analysis from the POPular Genetics and POPular Age trials CYP2C19 alleles in elderly patients. <i>International Journal of Cardiology</i> , 2021, 334, 10-17.	0.8	4
31	The effect of acenocoumarol on the antiplatelet effect of clopidogrel. <i>Thrombosis and Haemostasis</i> , 2015, 114, 708-716.	1.8	3
32	Effect of Tailored Antiplatelet Therapy to Reduce Recurrent Stent Thrombosis and Cardiac Death After a First Episode of Stent Thrombosis. <i>American Journal of Cardiology</i> , 2017, 119, 1500-1506.	0.7	3
33	Safety of Ticagrelor Compared to Clopidogrel after Prehospital Initiation of Treatment. <i>TH Open</i> , 2018, 02, e357-e368.	0.7	3
34	Efficacy and safety of glycoprotein IIb/IIIa inhibitors in addition to P2Y ₁₂ inhibitors in ST-segment elevation myocardial infarction: A subanalysis of the POPular Genetics trial. <i>Catheterization and Cardiovascular Interventions</i> , 2022, 99, 676-685.	0.7	3
35	Value of CYP2C19 *2 and *17 Genotyping in Clinical Practice. Promising but Not Ready Yet. <i>Revista Española De Cardiología (English Ed)</i> , 2012, 65, 205-207.	0.4	2
36	Effect of CYP3A4*22 and PPAR- α Genetic Variants on Platelet Reactivity in Patients Treated with Clopidogrel and Lipid-Lowering Drugs Undergoing Elective Percutaneous Coronary Intervention. <i>Genes</i> , 2020, 11, 1068.	1.0	2

#	ARTICLE	IF	CITATIONS
37	Reloading When Switching From Ticagrelor or Prasugrel to Clopidogrel Within 7 Days After STEMI. JACC: Cardiovascular Interventions, 2020, 13, 663-665.	1.1	1
38	Platelet Function Testing in Clinical Practice – Experience and Views from Europe and the US. European Cardiology Review, 2011, 7, 203.	0.7	1